Where does Bernard Gilly work?

Bernard Gilly is Chairman (Président) at iBionext.

Bernard Gilly

Investor

Chairman (Président) at iBionext

Paris, Île-de-France, France

Find your path to Bernard

188 people in our graph share verified history with Bernard — schools, employers, funds. One of them is your warm intro.

Walter OlesiakunlockedBernard: together at PMC / Sanofi Pasteur (1989–1991)

×10Bernard: together at PMC / Sanofi Pasteur

Bernard: together at Sofinnova Partners

About

Bernard Gilly is CEO of BrainEver, a biopharmaceutical company developing therapeutic solutions for age-related neurodegenerative diseases including ALS and Parkinson's disease, with preclinical studies planned to advance to clinical trials by 2025. He is also president of Ibionext, an investment fund founded in 2012 that backs biotech and medtech companies. His background includes co-founding Gensight Biologics and Fovea Pharmaceuticals (sold to Sanofi for €370 million), serving as president and CEO of Transgene during its public listing on Euronext and Nasdaq in 1998, and working as a partner at Sofinnova Partners from 2000 to 2005.

Contact· self-published, not guessed

b•••@ibionext.comreveal

Experience

BrainEverCEOcurrent2015 — presentParis
iBionextChairmancurrent2015 — present
GenSight BiologicsCEO2013 — 2024
Fovea Pharmaceuticals / SanofiCEO2005 — 2012
Sofinnova PartnersPartner2000 — 2005
TransgeneCEO1992 — 2000
PMC / Sanofi PasteurVP R&D1987 — 1994

Skills & more

Languages Anglais · Français

From Bernard's professional profile.

Colleagues at iBionext

Alexia Perouse

Managing Partner and CEO at iBionext

Jean-Christophe Dantonel

Managing Partner at iBionext

Stéphane Losik

Middle Office Manager & Investor Support at iBionext

Frequently asked questions

Who is Bernard Gilly?: Bernard Gilly is CEO of BrainEver, a biopharmaceutical company developing therapeutic solutions for age-related neurodegenerative diseases including ALS and Parkinson's disease, with preclinical studies planned to advance to clinical trials by 2025. He is also president of Ibionext, an investment fund founded in 2012 that backs biotech and medtech companies. His background includes co-founding Gensight Biologics and Fovea Pharmaceuticals (sold to Sanofi for €370 million), serving as president and CEO of Transgene during its public listing on Euronext and Nasdaq in 1998, and working as a partner at Sofinnova Partners from 2000 to 2005.
Where does Bernard Gilly work?: Bernard Gilly is Chairman (Président) at iBionext.